News

A case report describes image-guided surgical excision combined with adjunctive cryotherapy and a single anterior chamber methotrexate injection, with no recurrence at 10 months.

In part 2 of a 2-part Q&A, John Berdahl, MD, weighs in on AI-driven IOL power calculation in challenging eyes, best practices for reducing posterior capsule opacification, and how surgical mission work abroad has shaped his approach in the OR.

Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module

The FDA approved the TECNIS PureSee IOL (model ZEN00V) on March 12, 2026.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.

A newly developed diagnostic system, CaptureTumor (CaT), driven by artificial intelligence (AI) and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation” for detecting rare ocular surface malignancies.

In part 1 of a 2-part Q&A, John Berdahl, MD, discusses the widening global cataract surgical gap and examines emerging evidence linking cataract extraction to a reduced risk of dementia.

Guidance includes building on existing science, reducing redundant testing, and accelerating treatments for rare and life-threatening diseases

NYU Langone’s Jordan Mandell, MD, and Ariana Levin, MD, sit down with UCLA’s Anne Coleman, MD, to discuss her recent study on cardiovascular risk scores and their association with glaucoma, AMD, and other ocular diseases.

The company confirmed it does not plan to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA)

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.

The study, led by researchers at Keio University School of Medicine, measured near add power in 6258 patients aged 40 to 79.

Andrew G. Lee, MD, and Drew Carey, MD, discuss recurrence of papilledema after discontinuation of GLP-1 receptor agonists and the implications for monitoring patients with idiopathic intracranial hypertension.

Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Knowing pregnancy-related risks enhances patient safety.

Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

Off-label use of laboratory-grade dye preparation found to harbor Sarocladium kiliense beyond the sterilizing capacity of standard filtration.

Learning Brazilian Portuguese boosts brain resilience and may delay dementia symptoms, but a humorous lesson highlights the realities of health care paperwork and waiting rooms.

The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.